Literature DB >> 20690028

Comparative immunolocalisation of perlecan with collagen II and aggrecan in human foetal, newborn and adult ovine joint tissues demonstrates perlecan as an early developmental chondrogenic marker.

Susan M Smith1, Cindy Shu, James Melrose.   

Abstract

We undertook a comparative immunolocalisation study on type II collagen, aggrecan and perlecan in a number of 12- to 14-week-old human foetal and postnatal (7-19 months) ovine joints including finger, toe, knee, elbow, hip and shoulder. This demonstrated that perlecan followed a virtually identical immunolocalisation pattern to that of type II collagen in the foetal tissues, but a slightly divergent localisation pattern in adult tissues. Aggrecan was also localised in the cartilaginous joint tissues, which were clearly delineated by toluidine blue staining and the type II collagen immunolocalisations. It was also present in the capsular joint tissues and in ligaments and tendons in the joint, which stained poorly or not at all with toluidine blue. In higher power microscopic views, antibodies to perlecan also stained small blood vessels in the synovial lining tissues of the joint capsule; however, this was not discernable in low power macroscopic views where the immunolocalisation of perlecan to pericellular regions of cells within the cartilaginous rudiments was a predominant feature. Perlecan was also evident in small blood vessels in stromal connective tissues associated with the cartilage rudiments and with occasional nerves in the vicinity of the joint tissues. Perlecan was expressed by rounded cells in the enthesis attachment points of tendons to bone and in rounded cells in the inner third of the meniscus, which stained prominently with type II collagen and aggrecan identifying the chondrogenic background of these cells and local compressive loads. Flattened cells within the tendon and in the surface laminas of articular cartilages and the meniscus did not express perlecan. Collected evidence presented herein, therefore, indicates that besides being a basement membrane component, perlecan is also a marker of chondrogenic cells in prenatal cartilages. In postnatal cartilages, perlecan displayed a pericellular localisation pattern rather than the territorial or interterritorial localisation it displayed in foetal cartilages. This may reflect processing of extracellular perlecan presumably as a consequence of intrinsic biomechanical loading on these tissues or to divergent functions for perlecan and type II collagen in adult compared to prenatal tissues.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20690028     DOI: 10.1007/s00418-010-0730-x

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  51 in total

Review 1.  Fibrocartilage in tendons and ligaments--an adaptation to compressive load.

Authors:  M Benjamin; J R Ralphs
Journal:  J Anat       Date:  1998-11       Impact factor: 2.610

2.  Boundary mode frictional properties of engineered cartilaginous tissues.

Authors:  J P Gleghorn; A R C Jones; C R Flannery; L J Bonassar
Journal:  Eur Cell Mater       Date:  2007-08-04       Impact factor: 3.942

Review 3.  Basement membrane proteoglycans: from cellar to ceiling.

Authors:  Renato V Iozzo
Journal:  Nat Rev Mol Cell Biol       Date:  2005-08       Impact factor: 94.444

4.  Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.

Authors:  Sarah Knox; Catherine Merry; Sally Stringer; James Melrose; John Whitelock
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

5.  Electrophoretic, biosensor, and bioactivity analyses of perlecans of different cellular origins.

Authors:  S Knox; J Melrose; J Whitelock
Journal:  Proteomics       Date:  2001-12       Impact factor: 3.984

6.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

Review 7.  Role of perlecan in skeletal development and diseases.

Authors:  John Hassell; Yoshihiko Yamada; Eri Arikawa-Hirasawa
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

8.  Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded.

Authors:  Tonia L Vincent; Monika A Hermansson; Ulrich N Hansen; Andrew A Amis; Jeremy Saklatvala
Journal:  Arthritis Rheum       Date:  2004-02

Review 9.  Clinical features of the congenital vitreoretinopathies.

Authors:  A O Edwards
Journal:  Eye (Lond)       Date:  2008-02-29       Impact factor: 3.775

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  28 in total

1.  Regional variations in the distribution and colocalization of extracellular matrix proteins in the juvenile bovine meniscus.

Authors:  Eric J Vanderploeg; Christopher G Wilson; Stacy M Imler; Carrie Hang-Yin Ling; Marc E Levenston
Journal:  J Anat       Date:  2012-06-18       Impact factor: 2.610

Review 2.  Histochemistry and cell biology: the annual review 2010.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2011-01-29       Impact factor: 4.304

3.  Proteoglycans in Normal and Healing Skin.

Authors:  Margaret Mary Smith; James Melrose
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-03-01       Impact factor: 4.730

4.  Perlecan modulates VEGF signaling and is essential for vascularization in endochondral bone formation.

Authors:  Muneaki Ishijima; Nobuharu Suzuki; Kentaro Hozumi; Tomoya Matsunobu; Keisuke Kosaki; Haruka Kaneko; John R Hassell; Eri Arikawa-Hirasawa; Yoshihiko Yamada
Journal:  Matrix Biol       Date:  2012-03-07       Impact factor: 11.583

Review 5.  Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers.

Authors:  Chiara Poluzzi; Renato V Iozzo; Liliana Schaefer
Journal:  Adv Drug Deliv Rev       Date:  2015-10-27       Impact factor: 15.470

6.  Chondroitin sulphate and heparan sulphate sulphation motifs and their proteoglycans are involved in articular cartilage formation during human foetal knee joint development.

Authors:  James Melrose; Marc D Isaacs; Susan M Smith; Clare E Hughes; Christopher B Little; Bruce Caterson; Anthony J Hayes
Journal:  Histochem Cell Biol       Date:  2012-05-23       Impact factor: 4.304

7.  Comparative immunolocalisation of fibrillin-1 and perlecan in the human foetal, and HS-deficient hspg2 exon 3 null mutant mouse intervertebral disc.

Authors:  Anthony J Hayes; Susan M Smith; James Melrose
Journal:  Histochem Cell Biol       Date:  2012-10-27       Impact factor: 4.304

8.  Comparative immunolocalisation of perlecan, heparan sulphate, fibroblast growth factor-18, and fibroblast growth factor receptor-3 and their prospective roles in chondrogenic and osteogenic development of the human foetal spine.

Authors:  Cindy Shu; Susan S Smith; Christopher B Little; James Melrose
Journal:  Eur Spine J       Date:  2013-02-10       Impact factor: 3.134

Review 9.  Nondestructive Techniques to Evaluate the Characteristics and Development of Engineered Cartilage.

Authors:  Joseph M Mansour; Zhenghong Lee; Jean F Welter
Journal:  Ann Biomed Eng       Date:  2016-01-27       Impact factor: 3.934

10.  FOXO1 and FOXO3 transcription factors have unique functions in meniscus development and homeostasis during aging and osteoarthritis.

Authors:  Kwang Il Lee; Sungwook Choi; Tokio Matsuzaki; Oscar Alvarez-Garcia; Merissa Olmer; Shawn P Grogan; Darryl D D'Lima; Martin K Lotz
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.